UCBG 2-08: 5-year efficacy results from the UNICANCER-PACS08 randomised phase III trial of adjuvant treatment with FEC100 and then either docetaxel or ixabepilone in patients with early-stage, poor prognosis breast cancer

Mario Campone, Magali Lacroix-Triki, Lise Roca, Marc Spielmann, Hans Wildiers, Paul Cottu, Pierre Kerbrat, Christelle Levy, Isabelle Desmoulins, Thomas Bachelot, Tan Winston, Jean Christophe Eymard, Lionel Uwer, Francois P. Duhoux, Didier Verhoeven, Dominique Jaubert, David Coeffic, Hubert Orfeuvre, Jean Luc Canon, Bernard AsselainAnne Laure Martin, Jerome Lemonnier, Henri Roché

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Fingerprint

Dive into the research topics of 'UCBG 2-08: 5-year efficacy results from the UNICANCER-PACS08 randomised phase III trial of adjuvant treatment with FEC100 and then either docetaxel or ixabepilone in patients with early-stage, poor prognosis breast cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences